NCT03922464已完成4 期
A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-lactic Acid (Sculptra® Aesthetic) for the Treatment of Contour Deformities of the Buttocks Region
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Percentage of subjects to achieve a one-point increase or higher since Baseline, on the Global Aesthetic Improvement Scale (GAIS) at Visit 6
研究概览
简要总结
This is a phase IV prospective, multicentre, single cohort, open-label clinical trial evaluating the efficacy and safety of Poly-L-lactic acid (Sculptra® Aesthetic) for the treatment of contour deformities of the buttocks region
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Age between 30 and 60 years;
- •Indication for treatment of bilateral contour deformities;
- •Mild to moderate flaccidity in the area to be treated, according to investigator's assessment;
- •An intact immune system, as the bio-stimulatory effect of Sculptra® Aesthetic is dependent on the host response. An intact immune system, as the bio-stimulatory effect of Sculptra® Aesthetic is dependent on the host response. Immune function will be evaluated through clinical history. Exclusions will consist of both primary (genetic) and secondary (acquired) immune deficiencies. Examples include: HIV/AIDS, chemotherapy, cancers (e.g., leukemia and lymphoma), certain autoimmune diseases (e.g., myasthenia gravis, systemic lupus erythematosus), certain medications (e.g., corticosteroids, tumor necrosis factor inhibitors, anticonvulsants), and certain chronic or congenital diseases. Any type of comorbidity or clinical condition will be reviewed at the investigator's discretion.
- •. Subjects who understood and signed the Informed Consent Form (ICF) when entering the study, before performing any investigational procedure.
排除标准
- •Prior (i.e., <1 year) or planned use (for the duration of the study period) any other aesthetic treatment in the buttock region, such as radiofrequency, cryolipolysis, dermal subscision, plastic surgery, laser treatment, chemical peeling or any other procedure based on active dermal response;
- •Any type of comorbidity or clinical condition that, at investigator's discretion, could interfere with study assessments;
- •Using or planning to initiate restrictive diets (at investigator's discretion);
- •Using or planning to initiate use of supplements for weight loss;
- •Diabetes mellitus type 1 or type 2;
- •Autoimmune diseases, collagenosis, decompensated endocrine diseases or any disease that, at investigator's discretion, could interfere with study assessments;
- •Using or have used within the previous 3 months drugs such as corticosteroids, immunosuppressants, anticoagulants or other collagen-production inhibitors;
- •Initiated use of hormones or change in dose of hormonal replacement therapy within 3 months;
- •Practices regularly or intend to practice during the study high-performance or impact physical activities, such as weight lifting, marathon, triathlon;
- •Pregnant or breastfeeding, or wishes to get pregnant within the next 18 months, or refuses to use appropriate contraceptive method (in case of women of childbearing potential);
- •Sculptra® Aesthetic should not be used in any person who has hypersensitivity to any of the components of the product;
- •Active skin inflammation or infection in or near the treatment area;
- •Sculptra® Aesthetic should not be used in patients with known history of or susceptibility to keloid formation or hypertrophic scarring;
- •Sculptra® Aesthetic should not be used in patients with implants in the treated regions;
- •Possessing any of the contraindications for use of Sculptra® Aesthetic.
结局指标
主要结局
Percentage of subjects to achieve a one-point increase or higher since Baseline, on the Global Aesthetic Improvement Scale (GAIS) at Visit 6
时间窗: Month 6
次要结局
- Assessment of adverse events (AEs) at all study visits (Visits 0-6). The incidence, seriousness, severity and relationship with the medical device of AEs reported will be evaluated.(All visits, Baseline to Month 6)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticitySpasticity, MuscleNCT03908580Medy-Tox120
已完成
4 期
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic ArthritisNCT03301883Hoffmann-La Roche62
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
已完成
4 期
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the KneeOsteoarthritis of KneeNCT02682524Daewon Pharmaceutical Co., Ltd.191
已完成
不适用
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® RegimenAtopic DermatitisNCT02073591Hyphens Pharma Pte Ltd58